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This lecture aims to provide an overview of renal cell
carcinoma (RCC) and insights into this rapidly evolving
treatment – image guided thermal ablative (IGA) ther-
apy. RCC is the commonest kidney cancer and the
detection of RCC has increased over the past decade.
There are over 8000 and 50,000 new cases/year in the
UK and USA respectively [1,2]. The increased detection
is due to wider usage of radiology (e.g. ultrasound or
computed tomography) and this usually results in the
detection of smaller RCC with earlier stage disease [3,4].
In addition, this is also related to the rise in incidence
in the general population as a result of smoking and
obesity [5-7].
The historical classical clinical triad where patients
presented with flank pain, abdominal mass and haema-
turia is now a rarity and nowadays the majority of the
incidentally detected RCCs are smaller and at an earlier
stage –T1 stage. However, historical data has suggested
that 60% of these small incidentally detected tumours
will grow gradually over a period of time [8]. Therefore,
there remains a clinical risk with adopting a ‘watchful
waiting’ approach for younger patients as these tumours
may become symptomatic or metastasize [9].
Open radical nephrectomy (RN) was the gold standard
treatment for RCC since it was introduced in 1869 and
Robson et al had popularized this treatment over the last
50 years [10].Over the past 10 years, laparoscopic RN is
becoming the standard of care with better cosmetic results
and shorter recovery time [11]. More recently for locally
confined (T1 disease) RCC treatment with nephron
sparing surgery (NSS) e.g. open/ laparoscopic PN has
demonstrated similar oncological durability to that of the
gold standard RN [12,13]. RN is now largely considered an
overtreatment for T1a (<4cm) RCC because it is associated
with greater nephron loss and earlier onset of chronic
kidney disease and also associated with increased cardio-
vascular events after RN [14,15].
Therefore, the current consensus is that RCC at stage
T1a (<4 cm), should be treated with minimally invasive
techniques in order to preserve renal function. Nephron
sparing surgery (NSS) with either laparoscopic/open PN
is advised whenever it is deemed technically possible
[16]. Although, the NSS has similar recurrence free and
long term survival outcomes as those with RN, NSS
remains technically challenging and associated with
significant morbidity even in expert hands [14,15].
Given the surgical challenges and the quest to preserve
renal function, IGA treatment of the smaller RCC with
radiofrequency ablation (RFA), cryoablation (CRYO) and
microwave (MWA) has evolved rapidly over the last
decade. Today, IGA of RCC has proven to be a safe and
effective treatment option and good oncological outcome
data is emerging for RFA [17-22] and CRYO [23,24]. In
the hands of an experienced interventional oncologist, the
primary technical success is now approaching >95% for
both IGA with RFA and CRYO. As RFA was introduced
earlier, the emerging larger RFA series have demonstrated
cancer specific survival of 97-100% with a follow up of
61-78 months [17-22].
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